Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Drug restores hair growth in patients with alopecia areata

Novel Novartis malaria compound shows potential to be effective against infections resistant to all …

Can nicotine protect the aging brain?

FDA launches #NaloxoneApp competition to spur innovative technologies to help reduce opioid overdose …

CHIC Project Survey: Your Opinion Counts

Historical analysis examines sugar industry role in heart disease research

Bristol-Myers Squibb awards first "Golden Tickets" for LabCentral to PanTher, Suono Bio

Gene therapy technique may help prevent cancer metastasis

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 billion

Review article takes rare look at impact of advertising psychiatric drugs

Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy …

Special T cells that target solid tumors offer potential treatment for pediatric and adult cancer

Pfizer launches new "Moodivator" app to help support, encourage and motivate people with d …

Many adults who screen positive for depression don't receive treatment

Intrexon partners with a pair of its fund portfolio startups

NeuroDerm's minipump passes the patient test

Microcap BioLineRx in-licenses a second NASH candidate under Novartis deal

Chutes & Ladders: Emma Walmsley will be the new CEO at GSK

PhIII Alzheimer’s flop takes chunk out of Lundbeck, hits Axovant with aftershocks

AC Immune upsizes IPO, hits bottom of range, netting $58M for neurodegeneration R&D

UniQure CEO quits after 9 months in the job

Teva posts positive tardive dyskinesia data, sets up Neurocrine battle

EuroBiotech:​ ​More​ ​Articles​ ​of​ ​Note

Gilead dumps late-stage colitis program after failing to find benefit

Zuckerberg and Chan latest wealthy philanthropists to attempt to ‘cure all disease’

German next-gen checkpoint inhibitor startup reels in €40M

Investors go bargain shopping as Novan IPO prices low, climbs high

Zombie biotech Eleven Bio seeks resurrection with merger deal

Genentech lays $310M wager on BioNTech’s mRNA cancer vaccine platform

Look back at pharma news to Sept 23

We’re on your side, NICE boss Sir Andrew Dillon tells pharma

FDA approves Amgen’s Amjevita as a biosimilar to Humira

Novartis receives three new FDA approvals for the expanded use of Ilaris

Janssen files BLA for US approval of sirukumab for rheumatoid arthritis

NICE in U-turn over Alexion's Strensiq

Sarepta Therapeutics prices $300 million public offering

Paul Campanelli named president and CEO of Endo International

Gilead halts study of GS-5745 for ulcerative colitis after it fails to show efficacy

NICE backs Gilead’s hepatitis C drug Epclusa

Novartis leads way in new class of malaria treatments

Teva to file for approval of SD-809 following more positive top-line Ph III results in tardive dyski …

Lundbeck fails with Phase III trial of idalopirdine in Alzheimer's

Government reforms will see Australian pharmaceutical market surpass $25 billion by 2020

Takeda and Affilogic collaborate to develop Nanofitin-based therapies in CNS

Medical News Today: Inflammation turns mitochondria into toxic factories

Medical News Today: Nicotine has the potential to prevent brain aging, study suggests

Medical News Today: Depression After Abortion: Understanding and Coping

Medical News Today: Antidepressant success affected by environmental conditions

Medical News Today: Hormone changes during menstrual cycle alter problem-solving strategies

Medical News Today: Hookworm Infection: Causes, Symptoms, and Treatment

Medical News Today: City design, transport may reduce global burden of disease and injury

Medical News Today: ALS could be prevented with technique that halts protein clumping

Medical News Today: Unused dental surgery prescriptions may help fuel opioid epidemic

Medical News Today: Existence of exercise-induced muscle memory challenged

Medical News Today: Long-term alcohol dependence affects cognitive abilities

Medical News Today: Anticellulite Creams: Are They Worth Your Money?

Medical News Today: Curiosity about cigarettes, cigars falling among students

Medical News Today: Oxytocin may intensify spiritual beliefs

Medical News Today: Cancer: Shutting down fat synthesis in cancer cells stunts tumor growth

EU approves Allergan’s IBS drug

Lundbeck reveals Alzheimer’s drug trial failure

NHS England unveils funding plan for general practice

Trial shows personalised medicine benefit in cancer patients

AstraZeneca pulls application for ovarian cancer drug

Gilead pulls plug on ulcerative colitis drug

UN signs historic declaration to fight AMR

NICE backs restricted use of Alexion’s Strensiq

Bayer and Evotec form kidney disease research pact

Allergan buys Tobira for up to $1.7bn

BMS’ Opdivo gets EU review for bladder cancer

Imperial Innovations streams £5.1m into new biotech Artios

Sanofi sues Merck for infringing Lantus patents

FDA OKs first Duchenne muscular dystrophy drug

600 GP practices could close by 2020, warns RCGP

More News